^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carmustine

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    5d
    CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=113, Active, not recruiting, Alliance for Clinical Trials in Oncology
    Trial completion date
    |
    cytarabine • etoposide IV • carmustine • thiotepa
    11d
    Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (clinicaltrials.gov)
    P1, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    temozolomide • carmustine • Zynyz (retifanlimab-dlwr)
    11d
    Development of a fatty acid metabolism (FAM)-related gene signature for prognosis prediction and personalized therapy in lower grade gliomas. (PubMed, Transl Cancer Res)
    Drug sensitivity analysis indicated that high-risk individuals might be more responsive to chemotherapy, particularly temozolomide and carmustine. This study underscores the prognostic role of the FAM-related risk model for LGGs. Assessing patient risk scores through this model could help tailor personalized treatments, providing valuable guidance for clinical decision-making.
    Journal • Gene Signature • IO biomarker
    |
    CPT2 (Carnitine Palmitoyltransferase 2)
    |
    temozolomide • carmustine
    14d
    Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single-Cell and Spatial Transcriptomics. (PubMed, Ann Clin Transl Neurol)
    Fibroblasts drive glioma recurrence, with AEBP1, ZNF708, and TSHZ2 predicting recurrence and chemoresistance. These genes promote immune suppression (via plasma cells) and activate recurrence pathways. Oligodendrocyte-astrocyte interactions shape the recurrent microenvironment, suggesting new therapeutic targets.
    Journal • IO biomarker
    |
    AEBP1 (AE Binding Protein 1) • IL17A (Interleukin 17A)
    |
    cisplatin • irinotecan • vincristine • carmustine
    2ms
    Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2027 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab) • Starasid (cytarabine ocfosfate)
    2ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Recruiting, Thomas Jefferson University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Aug 2032 | Trial primary completion date: May 2030 --> Oct 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)
    2ms
    Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • plerixafor
    2ms
    hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)
    P2, N=16, Recruiting, Leland Metheny | Suspended --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH2 mutation
    |
    temozolomide • carmustine • Neupogen (filgrastim)
    2ms
    The effect of combination therapy on Bevacizumab, Carmustine, and Metformin chemotherapy drugs on the fluctuating performance expression of TLR2, TLR6, and IL-6 genes in the cell line of brain glioblastoma. (PubMed, Cancer Cell Int)
    The combination of bevacizumab, carmustine, and metformin exerts a potent synergistic antitumor effect in U87MG glioblastoma cells through modulation of inflammation-associated genes, induction of apoptosis, and disruption of cell cycle progression. These findings provide a mechanistic rationale for multi-targeted combination therapy in glioblastoma and support further preclinical evaluation.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TLR2 (Toll Like Receptor 2)
    |
    Avastin (bevacizumab) • carmustine • metformin
    3ms
    Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov)
    P2, N=150, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    |
    ALK positive
    |
    cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Depocyte (liposomal cytarabine) • Neupogen (filgrastim)
    3ms
    A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=40, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • carmustine • melphalan
    3ms
    Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
    P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Trial completion date: Feb 2027 --> Mar 2032 | Trial primary completion date: Jan 2027 --> May 2030
    Trial completion date • Trial primary completion date
    |
    carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)